Compare Ascendis Pharma A/S (ASND) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Intel Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Intel Corp trades at $106.56 (market cap $552.06B). The key difference: Intel Corp is far larger — about 31.1× Ascendis Pharma A/S's market cap, and Intel Corp pays a 2.24% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | INTC | |
|---|---|---|
Market Cap | $17.74B | $552.06B |
Sector | Health | Technology |
52-Week High | $277.18 | $140.94 |
52-Week Low | $163.32 | $19.31 |
Enterprise Value | $18.11B | $564.30B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Intel (INTC) trades at $109.84, down 2.4% on the day, with a bearish technical signal but recent earnings beats. The stock shows mixed fundamentals with a high P/E of 904.17 and negative net margin of -5.9%, though operating cash flow improved to $9.70B in 2025. News highlights government support and turnaround progress, with consensus price target at $99.70.
Outlook remains cautious due to profitability challenges and competitive pressures, but long-term growth potential exists from AI and foundry expansions. Key risks include execution on capital investments and market share loss to AMD. Analyst sentiment is mixed with 36.9% buy ratings, suggesting patience for turnaround results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
